Project Dynamo
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Investment Opportunity
US$40–60 million for 30%–49% equity stake
Partner with a proven, export-oriented specialty pharmaceutical company serving 200+ global pharma clients and positioned for high-growth in complex generics and innovative delivery systems.
Company Overview
Founded by pharmaceutical technocrats with 30+ years of experience, the company operates state-of-the-art GMP, EU-GMP, and WHO-compliant facilities. It has built a strong reputation in pellets, MUPS, nano-formulations, ophthalmics, and inhalation technologies.
Export presence across every continent
Patent-driven, innovation-led R&D culture
34 commercial products, 40+ PFIs (products under filing), and 15+ products in active development
Cutting-edge platforms:
– Soft Mist Inhaler (4 products)
– Nano-particle ophthalmology
– Transdermal liposomal technology
– Oncology sterile manufacturing
Key Platforms & Pipeline Highlights
Soft Mist Inhaler Platform: 100% aqueous, solvent-free, propellant-free; achieves higher lung deposition than DPI/MDI; applicable to multiple respiratory generics
Nano-Ophthalmology Platform: Brinzolamide nano-suspension with superior corneal/conjunctival absorption, reduced irritation & blurriness
Transdermal Liposomal Delivery: Enhanced absorption for iron, folic acid, vitamin D, B12; bypasses first-pass metabolism
Sublingual Nanoparticle Delivery: High-potential non-injectable alternative for biologics (e.g., GLP-1 formulations) under active development
Oncology: Complex sterile generics in pipeline
Pipeline momentum: 6–7 ANDA filings, 2 × 505(b)(2) programs (US & EU), contracts with major US/EU partners.
Market Drivers & Opportunity
Respiratory: Inhaler & nasal spray generic drugs market projected to grow significantly (recent estimates ~US$30–32B in 2024–2025, heading toward US$50–68B by early 2030s); COPD remains a major driver with large patient populations
Ophthalmology (Glaucoma): Global cases expected to nearly double to ~112 million by 2040; glaucoma accounts for substantial blindness burden (e.g., ~12.8% in India)
Nutraceutical/Transdermal: Widespread chronic deficiencies; high supplement usage among adults >45 (US data shows ~58–74% of adults take supplements, with strong demand for better-absorbed formats)
High-margin B2B model with regulatory and specialized formulation barriers to entry.
Financial Trajectory & Use of Funds
Historic Revenue
FY2022: US$12.7M
FY2023: US$20.4M
FY2024: US$22M
Projected Growth
FY2025: US$29M
FY2026: US$58M
FY2027: US$162M
FY2027 EBITDA projection: US$66M (driven by high gross margins from specialized products and scale)
Use of Funds
Manufacturing scale-up (new inhalation & ophthalmology facility ready FY27; oncology sterile facility; expanded pellet/granule capacity)
Regulatory approvals & filings acceleration
R&D for pipeline advancement
Global commercial & B2B/B2G market expansion
Project Dynamo offers a rare combination of proven execution, cutting-edge platforms, strong client base, and explosive projected growth in high-barrier specialty generics markets.